May
08
2024
(MedPage Today) -- Novo Nordisk cut the price of its blockbuster weight-loss and diabetes drug semaglutide (Wegovy, Ozempic). (Reuters)
In adults with increased fracture risk, once-weekly 1-mg semaglutide did not increase bone formation based... (Source: MedPage Today Endocrinology)
Read More
MedWorm •
Diabetes for Patients •